Genetic therapeutic approaches for duchenne muscular dystrophy

Human Gene Therapy

Volumn 23, Issue 7, 2012, Pages 676-687

  Foster, Helen ^a   Popplewell, Linda ^a   Dickson, George ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN;

ANTISENSE THERAPY; CELL THERAPY; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON SKIPPING; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; INVERTED TERMINAL REPEAT; NONHUMAN; REVIEW; RNA SPLICING; SPLICEOSOME; TRANSGENE; VIRUS GENE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; DYSTROPHIN; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION;

EID: 84864343619     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.099     Document Type: Review

References (147)

1. Aartsma-Rus, A., van Deutekom, J.C., Fokkema, I.F., et al. (2006). Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34, 135-144. (Pubitemid 44167796)
2. Aartsma-Rus, A., Fokkema, I., Verschuuren, J., et al. (2009). Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293-299.
3. Adams, A.M., Harding, P.L., Iversen, P.L., et al. (2007). Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: Cocktails and chemistries. BMC Mol. Biol. 8, 57.
4. Alter, J., Lou, F., Rabinowitz, A., et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175-177. (Pubitemid 43214742)
5. Alter, J., Sennoga, C.A., Lopez, D.M., et al. (2009). Microtubule stability is a major determinant of the efficiency of ultrasound and microtubule mediated in vivo gene transfer. Ultrasound Med. Biol. 35, 976-984.
6. Annoni, A., Brown, B.D., Cantore, A., et al. (2009). In vivo delivery of a microRNA-regulated transgene induces antigenspecific regulatory T cells and promotes immunologic tolerance. Blood 114, 5152-5161.
7. Arechavala-Gomeza, V., Graham, I.R., Popplewell, L.J., et al. (2007). Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum. Gene Ther. 18, 798-810. (Pubitemid 47502846)
8. Arnoud, S., Perez, C., Cabaniols, J.P., et al. (2007). Engineered ICreI derivatives cleaving sequences from the human XPC gene can induce highly efficient gene correction in mammalian cells. J. Mol. Biol. 371, 49-65. (Pubitemid 47030453)
9. BaNKs, G.B., Combs, A.C., Chamberlain, J.R., and Chamberlain, J.S. (2008). Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Hum. Mol. Genet. 17, 3975-3986. (Pubitemid 352762858)
10. BaNKs, G.B., Chamberlain, J.S., and Froehner, S.C. (2009). Truncated dystrophins can influence neuromuscular synapse structure. Mol. Cell. Neurosci. 40, 433-441.
11. BaNKs, G.B., Judge, L.M., Allen, J.M., and Chamberlain, J.S. (2010). The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 6, e1000958.
12. Beroud, C., Tuffery-Giraud, S., Matsuo, M., et al. (2007). Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum. Mutat. 28, 196-202. (Pubitemid 46233317)
13. Bertoni, C. (2005). Oligonucleotide-mediated gene editing for neuromuscular disorders. Acta Myol. 24, 194-201.
14. Bertoni, C., Morris, G.E., and Rando, T.A. (2005). Strand bias in oligonucleotide-mediated dystrophin gene editing. Hum. Mol. Genet. 14, 221-233.
15. Bish, L.T., Sleeper, M.M., Forbes, S.C., et al. (2012). Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol. Ther. 20, 580-589.
16. Boothroyd, C.E., Dreesen, O., Leonova, T., et al. (2009). A yeastendonuclease generated DNA break induces antigenic switching in Trypanosoma brucei. Nature 459, 278-281.
17. Bostick, B., Yue, Y., Lai, Y., et al. (2008). Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum. Gene Ther. 19, 851-856.
18. Bostick, B., Yue, Y., Long, C., et al. (2009). Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged mdx mice. Mol. Ther. 17, 253-261.
19. Bostick, B., Shin, J.H., Yue, Y., and Duan, D. (2011). AAVmicrodystrophin therapy improves cardiac performance in aged female mdx mice. Mol. Ther. 19, 1826-1832.
20. Boutin, S., Monteilhet, V., Veron, P., et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704-712.
21. Bowles, D.E., Mcphee, S.W., Li, C., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443-455.
22. Brown, B.D., Venneri, M.A., Zingale, A., et al. (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 12, 585-591.
23. Bushby, K., FiNKel, R., BirNKrant, D.J., et al. (2010). Diagnosis and management of Duchenne muscular dystrophy. 2. Implementation of multidisciplinary care. Lancet Neurol. 9, 177-189.
24. Carroll, D. (2011). Genome engineering with zinc-finger nucleases. Genetics 188, 773-782.
25. Chao, H., Mansfield, S.G., Bartel, R.C., et al. (2003). Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat. Med. 29, 1015-1019. (Pubitemid 37025113)
26. Chapdelaine, P., Pichavant, C., Rousseau, J., et al. (2010). Meganucleases can restore the reading frame of a mutated dystrophin. Gene Ther. 17, 846-858.
27. Chen, H.Y., Kathirvel, P., Yee, W.C., and Lai, P.S. (2009). Correction of dystrophia myotonica type 1 pre-mRNA transcripts by artificial trans-splicing. Gene Ther. 16, 211-217.
28. Choulika, A., Perrin, A., Dujon, B., and Nicolas, J.F. (1995). Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol. Cell. Biol. 15, 1968-1973.
29. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 378, 595-605.
30. Crawford, G.E., Faulkner, J.A., Crosbie, R.H., et al. (2000). Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J. Cell Biol. 150, 1399-1410.
31. Daboussi, F., Zaslavskiy, M., Poirot, L., et al. (2012). Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting endonucleases. Nucleic Acids Res. Epub ahead of print.
32. de Angelis, F.G., Sthandier, O., Berarducci, B., et al. (2002). Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin premRNA induce exon skipping and restoration of a dystrophin synthesis in D48-50 DMD cells. Proc. Natl. Acad. Sci. U.S.A. 99, 9456-9461. (Pubitemid 34764635)
33. Denti, M.A., Rosa, A., D'Antona, G., et al. (2006). Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc. Natl. Acad. Sci. U.S.A. 103, 3758-3763. (Pubitemid 43376628)
34. Denti, M.A., Incitti, T., Sthandier, O., et al. (2008). Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum. Gene Ther. 19, 601-608. (Pubitemid 351913531)
35. Dunckley, M.G., Eperon, I.C., and Dickson, G. (1996). Modulation of pre-mRNA splicing in the Duchenne muscular dystrophy gene. Biochem. Soc. Trans. 24, 276S. (Pubitemid 26165444)
36. England, S.B., Nicholson, L.V., Johnson, M.A., et al. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180-182.
37. Fabb, S.A., Wells, D.J., Serpente, P., and Dickson, G. (2002). Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum. Mol. Genet. 11, 733-741. (Pubitemid 34428641)
38. Fan, Z., Kocis, K., Valley, R., et al. (2012). Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy. Mol. Ther. 20, 456-461.
39. Ferrer, A., Wells, K.E., and Wells, D.J. (2000). Immune responses to dystropin: Implications for gene therapy of Duchenne muscular dystrophy. Gene Ther. 7, 1439-1446.
40. Foster, H., Sharp, P.S., Athanasopoulos, T., et al. (2008). Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol. Ther. 16, 1825-1832.
41. Ghosh, A., Yue, Y., Long, C., et al. (2007). Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. Mol. Ther. 15, 750-755. (Pubitemid 46431995)
42. Ghosh, A., Yue, Y., Lai, Y., and Duan, D. (2008). A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol. Ther. 16, 124-130.
43. Ghosh, A., Yue, Y., and Duan, D. (2011). Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum. Gene Ther. 22, 77-83.
44. Goemans, N.M., Tulinius, M., van den Akker, J.T., et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513-1522.
45. Goyenvalle, A., Vulin, A., Fougermousse, F., et al. (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exonskipping. Science 306, 1796-1799. (Pubitemid 39601401)
46. Goyenvalle, A., Seto, J.T., Davies, K.E., and Chamberlain, J. (2011). Therapeutic approaches to muscular dystrophy. Hum. Mol. Genet. 20, R69-R78.
47. Goyenvalle, A., Babbs, A., Wright, J., et al. (2012a). Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum. Mol. Genet. 21, 2559-2571.
48. Goyenvalle, A., Wright, J., Babbs, A., et al. (2012b). Engineering multiple U7snRNA constructs to induce single and multiexonskipping for Duchenne muscular dystrophy. Mol. Ther. 20, 1212-1221.
49. Graham, I.R., Hill, V.J., Manoharan, M., et al. (2004). Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): Target sequence optimisation using oligonucleotide arrays. J. Gene Med. 6, 1149-1158. (Pubitemid 40228127)
50. Gregorevic, P., BlaNKinship, M.J., Allen, J.M., et al. (2004). Systemic delivery of genes to striated muscles using adenoassociated viral vectors. Nat. Med. 10, 828-834. (Pubitemid 39070856)
51. Gregorevic, P., Allen, J.M., Minami, E., et al. (2006). rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787-789. (Pubitemid 44050067)
52. Gregorevic, P., Schultz, B.R., Allen, J.M., et al. (2009). Evaluation of vascular delivery methodolgies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol. Ther. 17, 1427-1433.
53. Halbert, C.L., Standaert, T.A., Wilson, C.B., and Miller, A.D. (1998). Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol. 72, 9795-9805. (Pubitemid 28520845)
54. Harper, S.Q., Hauser, M.A., Dellorusso, C., et al. (2002). Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261. (Pubitemid 34250103)
55. Igoucheva, O., Alexeev, V., and Yoon, K. (2001). Targeted gene correction by small single-stranded oligonucleotides in mammalian cells. Gene Ther. 8, 391-399. (Pubitemid 32241939)
56. Inagaki, K., Fuess, S., Storm, T.A., et al. (2006). Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45-53. (Pubitemid 43899488)
57. Ito, K., Kimura, S., Ozasa, S., et al. (2006). Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum. Mol. Genet. 15, 2266-2275. (Pubitemid 43985517)
58. Jensen, N.M., Dalsgaard, T., Jakobsen, M., et al. (2011). An update on targeted gene repair in mammalian cells: Methods and mechanisms. J. Biomed. Sci. 18, 10.
59. Jiang, H., Couto, L.B., Patarroyo-White, S., et al. (2006). Effects of transient immuno-suppression on adenoassociated, virusmediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108, 3321-3328.
60. Kayali, R., Bury, F., Ballard, M., and Bertoni, C. (2010). Sitedirected gene repair of the dystrophin gene mediated by PNAssODNs. Hum. Mol. Genet. 19, 3266-3281.
61. Kinali, M., Arechavala-Gomeza, V., Feng, L., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A singleblind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918-928.
62. Koo, T., Malerba, A., Athanasopoulos, T., et al. (2011a). Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of a1-syntrophin and a-dystrobrevin in skeletal muscles of mdx mice. Hum. Gene Ther. 22, 1379-1388.
63. Koo, T., Okada, T., Athanasopoulos, T., et al. (2011b). Long-term functional adeno-associated virusmicrodystrophin expression in the dystrophic CXMDj dog. J. Gene Med. 13, 497-506.
64. Kornegay, J.N., Li, J., Bogan, J.R., et al. (2010). Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol. Ther. 18, 1501-1508.
65. Lai, Y., and Duan, D. (2012). Progress in gene therapy of dystrophic heart disease. Gene Ther. 19, 678-685.
66. Lai, Y., Yue, Y., Liu, M., et al. (2005). Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 23, 1435-1439. (Pubitemid 41679397)
67. Lai, Y., Thomas, G.D., Yue, Y., et al. (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119, 624-635.
68. Li, H., Haurigot, V., Doyon, Y., et al. (2011). In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217-221.
69. Lin, A.Y., Prochniewicz, E., Henderson, D.M., et al. (2012). Impacts of dystrophin and utrophin domains on actin structural dynamics: Implications for therapeutic design. J. Mol. Biol. 420, 87-98.
70. Liu, C.M., Liu, D.P., and Liang, C.C. (2002a). Oligonucleotidemediated gene repair at DNA level: The potential applications for gene therapy. J. Mol. Med. 80, 620-628.
71. Liu, X., Jiang, Q., Mansfield, S.G., et al. (2002b). Partial correction of endogenous DF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat. Biotechnol. 20, 47-52. (Pubitemid 34044914)
72. Lombardo, A., Genovese, P., Beausejour, C.M., et al. (2007). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25, 1298-1306. (Pubitemid 350076515)
73. Longhese, M.P., Bonetti, D., Manfrini, N., and Clerici, M. (2010). Mechanisms and regulation of DNA end resection. EMBO J. 29, 2864-2874.
74. Lorain, S., Peccate, C., Le Hir, M., and Garcia, L. (2010). Exon exchange approach to repair Duchenne dystrophin transcripts. PLoS One 5, e10894.
75. Loufrani, L., Matrougui, K., Gorny, D., et al. (2001). Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation 103, 864-870. (Pubitemid 32163886)
76. Loufrani, L., Levy, B.I., and Henrion, D. (2002). Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. Circ.Res. 91, 1183-1189. (Pubitemid 36076368)
77. Lu, Q.L., Rabinowitz, A., Chen, Y.C., et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. U.S.A. 102, 198-203. (Pubitemid 40094452)
78. Maguire, K., Suzuki, T., DiMatteo, D., et al. (2009). Genetic correction of splice site mutation in purified and enriched myoblasts isolated from mdx5cv mice. BMC Mol. Biol. 10, 15.
79. Malerba, A., Thorogood, F.C., Dickson, G., and Graham, I.R. (2009). Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum. Gene Ther. 20, 955-965.
80. Malerba, A., Sharp, P.S., Graham, I.R., et al. (2011a). Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol. Ther. 19, 345-354.
81. Malerba, A., Boldrin, L., and Dickson, G. (2011b). Longterm systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: Implications for cardiac muscle integrity. Nucleic Acid Ther. 21, 293-298.
82. Manning, W.C., Zhou, S., Bland, M.P., et al. (1998). Transient immuno-suppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9, 477-485. (Pubitemid 28149601)
83. Manno, C.S., Arruda, V.R., Pierce, G.F., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347. (Pubitemid 43355084)
84. Mansfield, S.G., Kole, J., Puttaraju, M., et al. (2000). Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Ther. 7, 1885-1895.
85. Martin, S.A., Lord, C.J., and Ashworth, A. (2010). Therapeutic targeting of the DNA mismatch repair pathway. Clin. Cancer Res. 16, 5107-5113.
86. Martino, A.T., Nayak, S., Hoffman, B.E., et al. (2009). Tolerance induction to cytoplasmic b-galactosidase by hepatic AAV gene transfer: Implications for antigen presentation and immunotoxicity. PLoS One 4, e6376.
87. Matsumura, K., Burghes, A.H., Mora, M., et al. (1994). Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. J. Clin. Invest. 93, 99-105.
88. McClorey, G., Moulton, H.M., Iversen, P.L., et al. (2006a). Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 13, 1373-1381. (Pubitemid 44420632)
89. McClorey, G., Fall, A.M., Moulton, H.M., et al. (2006b). Induced dystrophin exon skipping in human muscle explants. Neuromuscul. Disord. 16, 583-590. (Pubitemid 44374319)
90. Mendell, J.R., Campbell, K., Rodino-Klapac, L., et al. (2010a). Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 363, 1429-1437.
91. Mendell, J.R., Rodino-Klapac, L.R., Rosales, X.Q., et al. (2010b). Sustained a-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol. 68, 629-638.
92. Mingozzi, F., and High, K.A. (2007). Immune responses to AAV in clinical trials. Curr. Gene Ther. 7, 316-324. (Pubitemid 47595774)
93. Mingozzi, F., Hasbrouck, N.C., Basner-Tschakarjan, E., et al. (2007a). Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110, 2334-2341. (Pubitemid 47523153)
94. Mingozzi, F., Maus, M.V., Hui, D.J., et al. (2007b). CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419-422. (Pubitemid 46559826)
95. Mingozzi, F., Meulenberg, J.J., Hui, D.J., et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114, 2077-2086.
96. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
97. Neri, M., Torelli, S., Brown, S., et al. (2007). Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul. Disord. 17, 913-918. (Pubitemid 350137731)
98. Odom, G.L., Gregorevic, P., Allen, J.M., et al. (2008). Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol. Ther. 16, 1539-1545.
99. Odom, G.L., Gregorevic, P., Allen, J.M., and Chamberlain, J.S. (2011). Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol. Ther. 19, 36-45.
100. Ohshima, S., Shin, J.H., Yuasa, K., et al. (2009). Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol. Ther. 17, 73-80.
101. Paques, F., and Duchateau, P. (2007). Meganucleases and DNA double-strand break-induced recombination: Perspectives for gene therapy. Curr. Gene Ther. 7, 49-66. (Pubitemid 46322288)
102. Pichavant, C., Aartsma-Rus, A., Clemens, P.R., et al. (2011). Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol. Ther. 19, 830-840.
103. Popplewell, L.J., Adkin, C., Arechavala-Gomeza, V., et al. (2010). Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials. Neuromuscul. Disord. 20, 102-110.
104. Popplewell L.J., Koo T.Y., Leclerc X., et al. (2012). Meganucleaseenhanced genome correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 22 (Suppl. 1), S9.
105. Qiao, C., Li, J., Zheng, H., et al. (2009). Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum. Gene Ther. 20, 1-10.
106. Rimessi, P., Sabatelli, P., Fabris, M., et al. (2009). Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin epxression in the mdx mouse. Mol. Ther. 17, 820-827.
107. Riviere, C., Danos, O., and Douar, A.M. (2006). Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther. 13, 1300.
108. Rodino-Klapac, L.R., Montgomery, C.L., Bremer, W.G., et al. (2010). Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol. Ther. 18, 109-117.
109. Rouet, P., Smih, F., and Jasin, M. (1994). Introduction of doublestrand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol. Cell. Biol. 14, 8096-8106. (Pubitemid 24373558)
110. Sakamoto, M., Yuasa, K., Yoshimura, M., et al. (2002). Microdystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem. Biophys. Res. Commun. 293, 1265-1272. (Pubitemid 34681078)
111. Sampaolesi, M., Blot, S., D'Antona, G., et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444, 574-579. (Pubitemid 44864430)
112. SchiNKel, S., Bauer, R., Bekeredjian, R., et al. (2012). Longterm preservation of cardiac structure and function after adeno-associated virus serotype 9-mediated microdystrophin gene transfer in mdx mice. Hum. Gene Ther. Epub ahead of print.
113. Sharland, A., Logan, G.J., Bishop, A., and Alexander, I.E. (2010). Liver-directed gene expression using recombinant AAV 2/8 vectors-a tolerogenic strategy for gene delivery? Discov. Med. 9, 519-527.
114. Shin, J.H., Nitahara-Kasahara, Y., Hayashita-Kinoh, H., et al. (2011). Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. Gene Ther. 18, 910-919.
115. Shin, J.H., Yue, Y., Srivastava, A., et al. (2012). A simplified immune suppression scheme leads to persistent micro-dystrophin expression in duchenne muscular dystrophy dogs. Hum. Gene Ther. 23, 202-209.
116. Sirsi, S.R., Schray, R.C., Wheatley, M.A., and Lutz, G.J. (2009). Formulation of ployactide-co-glycotic acid nanospheres for encapsulation and sustained release of poly(ethylene imine)-poly(ethylene glycol) copolymers complexed to oligonucleotides. J. Nanobiotech. 7, 1.
117. Tagalakis, A.D., Graham, I.R., Riddell, D.R., et al. (2001). Gene correction of the apolipoprotein (Apo) E2 phenotype to wildtype ApoE3 by in situ chimeraplasty. J. Biol. Chem. 276, 13226-13230.
118. Tahara, M., Pergolizzi, R.G., Kobayashi, H., et al. (2004). Transsplicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-igm x-liNKed immunodeficiency. Nat. Med. 10, 835-841. (Pubitemid 39070857)
119. Toromanoff, A., Cherel, Y., Guilbaud, M., et al. (2008). Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol. Ther. 16, 1291-1299. (Pubitemid 351866061)
120. Toromanoff, A., Adjali, O., Larcher, T., et al. (2010). Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol. Ther. 18, 151-160.
121. Townsend, D., BlaNKinship, M.J., Allen, J.M., et al. (2007). Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol. Ther. 15, 1086-1092. (Pubitemid 46813611)
122. Townsend, D., Yasuda, S., Li, S., et al. (2008). Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol. Ther. 16, 832-835. (Pubitemid 351587091)
123. Urnov, F.D., Miller, J.C., Lee, Y.L., et al. (2005). Highly efficient endogenous human gene correction using designed zincfinger nucleases. Nature 435, 646-651. (Pubitemid 40825505)
124. Vacek, M., Sazani, P., and Kole, R. (2003). Antisense-mediated redirection of mRNA splicing. Cell. Mol. Life Sci. 60, 825-833. (Pubitemid 36735113)
125. van Deutekom, J.C., Bremmer-Bout, M., Janson, A., et al. (2001). Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 10, 1547-1554. (Pubitemid 32734306)
126. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-2686.
127. van Putten, M., Hulsker, M., Nadarajah, V.D., et al. (2012). The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS One 7, e31937.
128. van Vliet, L., deWinter, C.L., van Deutekom, J.C., et al. (2008). Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med. Genet. 9, 105.
129. Wang, B., Li, J., and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. U.S.A. 97, 13714-13719.
130. Wang, Z., Zhu, T., Qiao, C., et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321-328. (Pubitemid 41094420)
131. Wang, Z., Allen, J.M., Riddell, S.R., et al. (2007a). Immunity to adeno-associated virus-mediated gene transfer in a randombred canine model of Duchenne muscular dystrophy. Hum. Gene Ther. 18, 18-26. (Pubitemid 46105461)
132. Wang, Z., Kuhr, C.S., Allen, J.M., et al. (2007b). Sustained AAVmediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther. 15, 1160-1166. (Pubitemid 46813619)
133. Wang, B., Li, J., Fu, F.H., and Xiao, X. (2009). Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J. Orthop. Res. 27, 421-426.
134. Williams, J.H., Schray, R.C., Sirsi, S.R., and Lutz, G. (2008). Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal mucles of mdx mice. BMC Biotechnol. 8, 35-48.
135. Wilton, S.D., Fall, A.M., Harding, P.L., et al. (2007). Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol. Ther. 15, 1288-1296. (Pubitemid 46965325)
136. Wu, B., Li, Y., Morcos, P.A., et al. (2009). Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol. Ther. 17, 864-871.
137. Wu, B., Xiao, B., Cloer, C., et al. (2011). One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol. Ther. 19, 576-583.
138. Yokota, T., Lu, Q.L., Partridge, T., et al. (2009). Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol. 65, 667-676.
139. Yokota, T., Hoffman, E., and Takeda, S. (2011). Antisense oligomediated multiple exon skipping in a dog model of Duchenne muscular dystrophy. Methods Mol. Biol. 709, 299-312.
140. Yuasa, K., Yoshimura, M., Urasawa, N., et al. (2007). Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther. 14, 1249-1260. (Pubitemid 47299950)
141. Yue, Y., Liu, M., and Duan, D. (2006). C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin- associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. Mol. Ther. 14, 79-87.
142. Yue, Y., Ghosh, A., Long, C., et al. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther. 16, 1944-1952.
143. Yin, H., Moulton, H.M., Betts, C., et al. (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum. Mol. Genet. 18, 4405-4414.
144. Yin, H., Moulton, H.M., Betts, C., et al. (2010). Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol. Ther. 18, 1822-1829.
145. Zhang, P., Sun, B., Osada, T., et al. (2012). Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease. Hum. Gene Ther. 23, 460-472.
146. Zhang, Y., and Duan, D. (2012). Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum. Gene Ther. 23, 98-103.
147. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J.E. (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073-1080. (Pubitemid 351737072)